Agenda

à la une

Alderaan Biotechnology presents latest developments in next generation anti-CD25 antibody at SITC Congress

17 novembre 2022

Alderaan Biotechnology ALD2510 antibody shows promising tolerability and efficacy results for treatment of gynecologic and breast cancers.

EN SAVOIR PLUS

Pierre Fabre; Atara: CHMP Recommends Approval of Atara Biotherapeutics’ EbvalloTM (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

17 novembre 2022

Atara Biotherapeutics, Inc. and Pierre Fabre today announced the CHMP of the EMA has adopted a positive opinion recommending the EC approval of EbvalloTM (tabelecleucel) as a monotherapy for treatment of adult and pediatric patients two years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy.

EN SAVOIR PLUS

s’abonner à notre newsletter

Notre Conseil d’Administration

Nos adhérents et Sponsors

This is a unique website which will require a more modern browser to work!

Please upgrade today!